Financial Results First Half 2020

Pillars of growth

R&D

Heavy bet for R&D
as a future
growth engine

conocer +

R&D&i
R&D

Heavy bet on R&D
as a future
growth engine

find out more

R&D&i
Biosimilar de Enoxaparina

Biosimilars

A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.
 

find out more

Bemiparina

Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.
 

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures

+119%

Net profit of the businessin 2019

+46%

2019 LMWHglobal sales

65 countries

LMWH presence through strategic alliances with international partners

6 plants

for manufacturing own and third-party products in Spain

€29,3 Mn

of investment in R&D in 2019 Commitment to innovation

7 countries

Direct presence through subsidiaries  to market Enoxaparin

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors

 

Last news on Rovi 

(See all items)

0

27/07/2020

First half 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

0

27/07/2020

First half 2020 Results Press Release

Download our press release published on 27 July to find out the financial results for the first half of 2020.

Last annual report

annualreport1

Annual Report 2019

Last regular
public information

annualreport1

Press release